secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196489
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q2 net loss $32.9M; positive HD data with up to 46% mHTT reduction; cash $154M into Q4 2025
--------------------------------------------------------------------------------

- Q2 net loss $32.9M vs $21.1M YoY; revenue $19.7M vs $22.1M; cash $154M, sufficient into Q4 2025.
- SELECT-HD: WVE-003 reduced mutant HTT up to 46%, statistically significant; slowing caudate atrophy; Takeda opt-in submitted.
- DMD: FORWARD-53 dystrophin data expected 3Q2024; WVE-N531 previously showed 53% exon skipping.
- AATD: RestorAATion-2 dosing initiated; proof-of-mechanism data expected 4Q2024.
- Obesity: WVE-007 FIH study expected Q1 2025; preclinical data at R&D Day Fall 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524196489/0001193125-24-196489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524196489/d875535d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer